Private Advisor Group LLC Purchases 128,070 Shares of Telix Pharmaceuticals Limited $TLX

Private Advisor Group LLC grew its position in Telix Pharmaceuticals Limited (NASDAQ:TLX) by 276.3% during the first quarter, Holdings Channel reports. The institutional investor owned 174,415 shares of the company’s stock after acquiring an additional 128,070 shares during the quarter. Private Advisor Group LLC’s holdings in Telix Pharmaceuticals were worth $1,669,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of TLX. Portland Investment Counsel Inc. raised its stake in shares of Telix Pharmaceuticals by 108.0% during the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock worth $2,063,000 after acquiring an additional 138,200 shares in the last quarter. Lazard Asset Management LLC lifted its position in Telix Pharmaceuticals by 118.6% during the fourth quarter. Lazard Asset Management LLC now owns 250,517 shares of the company’s stock valued at $1,876,000 after acquiring an additional 135,893 shares during the last quarter. Millennium Management LLC acquired a new stake in Telix Pharmaceuticals in the third quarter valued at approximately $1,883,000. Russell Investments Group Ltd. acquired a new stake in Telix Pharmaceuticals in the second quarter valued at approximately $975,000. Finally, Quadrature Capital Ltd acquired a new stake in Telix Pharmaceuticals in the fourth quarter valued at approximately $276,000.

Telix Pharmaceuticals Price Performance

Telix Pharmaceuticals stock traded down $0.64 during mid-day trading on Friday, reaching $11.14. 186,393 shares of the company traded hands, compared to its average volume of 200,727. The firm’s fifty day moving average is $10.36 and its two-hundred day moving average is $8.96. Telix Pharmaceuticals Limited has a fifty-two week low of $6.28 and a fifty-two week high of $16.94. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TLX. Citigroup reduced their price target on Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Wall Street Zen raised Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. Finally, Wedbush reiterated an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Insider Buying and Selling at Telix Pharmaceuticals

In related news, CEO Christian Behrenbruch acquired 33,435 shares of the company’s stock in a transaction dated Wednesday, April 29th. The shares were purchased at an average cost of $14.87 per share, with a total value of $497,178.45. Following the completion of the acquisition, the chief executive officer directly owned 20,742,935 shares of the company’s stock, valued at $308,447,443.45. This represents a 0.16% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Telix Pharmaceuticals Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.